Marta Salek

Marta Salek

Auto-generated profile, based on publicly available information

Marta Salek

St Jude Children’s Research Hospital, Memphis, TN

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2023 in Cancer Medicine
Verified
Journal Article
Open access
MSMarta Salek
Marta Salek
ASAllison Silverstein
Allison Silverstein
ATAlyssa Tilly
Alyssa Tilly
PGPascale Yola Gassant
Pascale Yola Gassant
SGSanjeeva Gunasekera
Sanjeeva Gunasekera
EKErica C Kaye
Erica C Kaye
Purpose: In this scoping review, we evaluated existing literature related to factors influencing treatment decision‐making for patients diagnosed with cancer in low‐ and middle‐income countries, noting factors that influence decisions to pursue treatment with curative versus non‐curative intent. We identified an existing framework for adult cancer developed in a high‐income country (HIC) context and described similar and novel factors relevant to low‐and middle‐income country settings.Methods: We used scoping review methodology to identify and synthesize existing literature on factors influencing decision‐making for pediatric and adult cancer in these settings. Articles were identified through an advanced Boolean search across six databases, inclusive of all article types from inception through July 2022.Results: Seventy‐nine articles were identified from 22 countries across six regions, primarily reporting the experiences of lower‐middle and upper‐middle‐income countries. Included articles largely represented original research (54%), adult cancer populations (61%), and studied patients as the targeted population (51%). More than a quarter of articles focused exclusively on breast cancer (28%). Approximately 30% described factors that influenced decisions to choose between therapies with curative versus non‐curative intent. Of 56 reported factors, 22 novel factors were identified. Socioeconomic status, reimbursement policies/cost of treatment, and treatment and supportive care were the most commonly described factors.Conclusions: This scoping review expanded upon previously described factors that influence cancer treatment decision‐making in HICs, broadening knowledge to include perspectives of low‐ and middle‐income countries. While global commonalities exist, certain variables influence treatment choices differently or uniquely in different settings. Treatment regimens should further be tailored to local environments with consideration of contextual factors and accessible resources that often impact decision‐making.

29 May 2022 in Journal of Pain and Symptom Management
Verified
Journal Article
Closed access
MSMarta Salek
Marta Salek
CWCameka Woods
Cameka Woods
MGMelanie Gattas
Melanie Gattas
JGJami S. Gattuso
Jami S. Gattuso
BMBelinda Mandrell
Belinda Mandrell
EKErica C Kaye
Erica C Kaye

28 November 2023 in The Lancet Oncology
Verified
Journal Article
Closed access
MSMarta Salek
Marta Salek
AMAlexandra Mueller
Alexandra Mueller
IAInna Alanbousi
Inna Alanbousi
ZCZuzanna Cepowska
Zuzanna Cepowska
MDMalgorzata Dutkiewicz
Malgorzata Dutkiewicz
SCSAFER Ukraine Collaborative
SAFER Ukraine Collaborative

25 April 2022 in Blood Advances
Verified
Journal Article
Open access
PDF file
MSMarta Salek
Marta Salek
NONinad Oak
Ninad Oak
MHMelissa Ruth Hines
Melissa Ruth Hines
JMJamie L. Maciaszek
Jamie L. Maciaszek
RTRuth Tatevossian
Ruth Tatevossian
PCPatrick K Campbell
Patrick K Campbell
Marta Salek, Ninad Oak, Melissa Ruth Hines, Jamie L. Maciaszek, Ruth Tatevossian, Akshay Sharma, Kim E Nichols, Patrick K Campbell; Development of BRAFV600E-pos

1 April 2026 in JCO Global Oncology
Verified
Journal Article
Open access
ACAndrea Cuviello
Andrea Cuviello
MSMarta Salek
Marta Salek
SHSri Andini Handayani
Sri Andini Handayani
SBSally Blair
Sally Blair
ACAnjali Chandra
Anjali Chandra
CLCatherine G. Lam
Catherine G. Lam
PURPOSE: Early integration of palliative care (PC) for children with cancer is vital to improved patient outcomes. Despite this, access to PC services for children in Asia Pacific (AP) is sparce. We aimed to explore potential barriers to PC provision in childhood cancer care across AP. METHODS: The Assessing Doctors' Attitudes on Palliative Treatment survey was revised for cultural context, translated into six languages, and distributed electronically to physicians who care for children with cancer. Descriptive statistics were used to summarize data. Secondary analyses used the Pearson chi-square test or Fisher exact test to examine associations between prior PC training and physician subspecialty with reported barriers. The McNemar test was applied to evaluate differences between actual versus ideal timing of PC consultations. Analysis of variance was conducted to compare mean values for perceived barriers across country income levels. RESULTS: Six hundred twenty-one physicians from 18 countries participated, with an overall response rate of 27% (621/2,305) and a median country response rate of 30% (range, 11%-85%). Most respondents (n = 366; 59%) believed PC should be consulted at diagnosis, but only 18% (n = 117) stated that this occurred in their clinical setting ( P < .001). The most highly ranked barriers to PC provision included limited physician knowledge (n = 511; 82%), lack of national health policy/advocacy (n = 494; 79%), lack of PC-trained clinicians (n = 492; 79%), lack of home-based services (n = 487; 78%), and physician discomfort in discussing PC (n = 483; 78%). Physicians practicing in lower-middle–income countries rated these barriers more significantly. CONCLUSION: Physicians report a discrepancy between ideal and actual timing of PC integration and identify several barriers to PC provision. Study findings will inform capacity building, education, and advocacy initiatives to improve the timing and quality of PC delivery in the region.

29 October 2024 in Supportive Care in Cancer
Verified
Journal Article
Open access
PDF file
MSMarta Salek
Marta Salek
APAmy S. Porter
Amy S. Porter
EMEssy Maradiege
Essy Maradiege
MDMae Concepcion J. Dolendo
Mae Concepcion J. Dolendo
DFDiego Figueredo
Diego Figueredo
PWPaul H. Wise
Paul H. Wise
Purpose Global childhood cancer survival outcomes correlate with regional contextual factors, yet upfront treatment decision-making for children with advanced or poor prognosis cancer in low- and middle-income countries (LMICs) is not well understood. This study aimed to (1) characterize the landscape of contextual factors that shape physician decision-making at diagnosis for these children in LMICs and (2) describe physician rationales for if/when to offer treatment with non-curative intent, including how they define “poor prognosis” during treatment decision-making. Methods An international panel of pediatric oncologists practicing in LMICs participated in two focus groups structured for the collaborative generation of factors influencing treatment decision-making, including consideration of non-curative treatment pathways at diagnosis. Thematic analysis of qualitative data was conducted, followed by member checking. Results Eleven pediatric oncologists participated, representing all global regions defined by the World Health Organization. Participants identified a broad range of factors influencing decision-making across multiple levels, including the individual, hospital, health system, community, and country levels. All participants agreed that treatment with non-curative intent could be offered at diagnosis in certain contexts, and diverse definitions for poor prognosis were described. Conclusions Upfront treatment decision-making for children with advanced or poor prognosis cancer in LMICs is variable and challenging. Difficulties with decision-making in LMICs may be amplified by inconsistent definitions of poor prognosis and underrepresentation of the factors that influence treatment decision-making within existing decision-making frameworks or childhood cancer treatment guidelines. Future research should explore decision-making approaches, preferences, and challenges in depth from the perspectives of pediatric cancer patients, families, and multidisciplinary clinicians.